Overview

Efficacy and Safety of LH-8 in Paediatric Alopecia Areata

Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Double-blind, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution versus placebo in children and adolescents with moderate to severe scalp alopecia areata. Phase 2/3 study performed in France, Germany, Bulgaria and India in 100 patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Legacy Healthcare SA
Treatments:
Pharmaceutical Solutions